t
IXICO plc announced on 16 May 2022 the date for an investor presentation related to its half-year results. CEO Giulio Cerroni and CFO Grant Nash will deliver the live presentation for existing and potential shareholders via the Investor Meet Company platform on 24 May 2022 at 4:30 pm BST.
| Date | 16 May 2022 |
| Time | 07:00:07 |
| Category | Results |
| ID | 4465L |
16 May 2022
IXICO plc
("IXICO", the "Company" or the "Group")
Half-year results investor presentation
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience today announces the date of its investor presentation to accompany its half-year results.
Investor presentation
Giulio Cerroni (CEO) and Grant Nash (CFO) will provide a live presentation relating to IXICO's half-year results via the Investor Meet Company platform on 24th May 2022 at 4.30pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via: https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.
For further information please contact:
|
IXICO plc |
+44 (0)20 3763 7499 |
|
|
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
|
|
|
|
|
|
Cenkos Securities PLC (Nominated adviser and sole broker) |
+44 (0)20 7397 8900 |
|
|
Giles Balleny / Max Gould (Corporate Finance) |
|
|
|
Michael F Johnson / Tamar Cranford-Smith (Sales) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com